Novo Nordisk Faces $70M Sales Rep OT Action
A subsidiary of Danish pharmaceutical giant Novo Nordisk A/S was slapped with a $70 million putative class and collective action in New York federal court Monday, which accuses the company of...To view the full article, register now.
Already a subscriber? Click here to view full article